key: cord-0943345-z1lvq0iv
authors: Lee, Sung-Eun; Lim, Ji-Young; Ryu, Da-Bin; Kim, Tae Woo; Park, Sung Soo; Jeon, Young-Woo; Yoon, Jae-Ho; Cho, Byung-Sik; Eom, Ki-Seong; Kim, Yoo-Jin; Kim, Hee-Je; Lee, Seok; Cho, Seok-Goo; Kim, Dong-Wook; Lee, Jong Wook; Min, Chang-Ki
title: Low frequency of CD3(+)CD4(+)CD161(+) T cells correlates with the occurrence of infections in refractory/relapsed multiple myeloma patients receiving lenalidomide plus low-dose dexamethasone treatment
date: 2018-06-25
journal: Ann Hematol
DOI: 10.1007/s00277-018-3401-y
sha: dfc6ff77e8a97e14ed02dba9db3eb068ed82ec95
doc_id: 943345
cord_uid: z1lvq0iv

The aim of this study was to explore the predictive implications of the composition of immune cell populations prior to lenalidomide plus high-dose dexamethasone (Len-Dex) initiation for the occurrence of infections. We prospectively examined immune cell populations in peripheral blood taken at baseline of lenalidomide plus low-dose dexamethasone (Len-dex) therapy and reviewed clinical and microbiology records in 90 patients with refractory/relapsed multiple myeloma (RRMM). Risk factors for infection were analyzed using logistic regression. During a median of 11 cycles of Len-dex treatment, 52 (57.8%) patients experienced at least 1 infection episode. Of a total of 92 episodes of infection, 58 (63%) episodes were clinically defined, 29 (31.5%) episodes were microbiologically defined, and 5 (5.4%) episodes were fever of unknown origin. Severe episodes were more frequently observed during the first 3 cycles. After adjusting for risk factors for infection based on univariate analyses, multivariate analyses showed that lower Hb (< 10 g/dL) was a clinically independent factor associated with occurrence of infections. Lower frequency (P = 0.044) and absolute count (P = 0.014) of circulating CD3(+)CD4(+)CD161(+) cells prior to Len-dex treatment were also associated with the occurrence of infection, especially during the first 3 cycles of Len-dex therapy. In addition to several clinical predictive factors, we found that CD3(+)CD4(+)CD161(+) cells may provide additional information for predicting the occurrence of infection in the early period of Len-dex therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00277-018-3401-y) contains supplementary material, which is available to authorized users.

Multiple myeloma (MM) is a clonal plasma cell neoplasm that presents variable clinical manifestations often referred to as CRAB symptoms (hyper-Calcemia, Renal insufficiency, Anemia, and/or Bone lesions) [1] . In addition to CRAB symptoms, infection is the leading cause of morbidity and mortality in MM; 26-45% of early deaths are attributable to infection [2, 3] .

The increased risk of infection seen in MM is due to disease-related immune deficits involving humoral immunity and various immune system components, including T cells [4] [5] [6] , dendritic cells [7] , and natural killer cells [8] . Treatment-related toxicity and the use of high-dose corticosteroid therapy also increase susceptibility to infection. A large longitudinal cohort study that The et al. conducted in patients with MM receiving current standard treatment with proteasome inhibitors (PIs), immune-modulatory drugs (IMiDs), and autologous stem cell transplantation revealed high-risk factors for infection such as late disease, multiple treatments, intensive combination systemic chemotherapy, and corticosteroid dose [9] .

Despite advances in the treatment of MM, most MM patients will nonetheless ultimately relapse or become refractory to current treatment, and so appropriate therapeutic options for patients with relapsed-refractory MM (RRMM) remain a focus of research. The treatment paradigm has shifted with the use of small biologic molecules (PIs, IMiDs and HDAC inhibitors). The effects of these drugs on the immune system are distinct from those of conventional anti-myeloma agents, resulting in changes in the types and patterns of infections. In particular, the combination of lenalidomide and high-dose dexamethasone (Len-Dex) demonstrated efficacy and safety in patients with relapsed/refractory MM in two large, welldesigned pivotal clinical trials [10, 11] . After that, lenalidomide plus low-dose dexamethasone (Len-dex) led to better overall survival and lower toxicity than Len-Dex in patients with newly diagnosed MM [12] and also remains the standard of care in the relapsed or refractory setting. Therefore, we analyzed the patterns and risks of infection in patients with RRMM during Len-dex treatment and sought to identify immune cell subtypes related to the occurrence of infection using multicolor flow cytometric analysis of fresh peripheral blood mononuclear cells (PBMCs) isolated from RRMM patients prior to Len-dex initiation.

Patients with RRMM who received salvage treatment with Len-dex at our institution were eligible for this study. The therapy regimen consisted of lenalidomide 25 mg once daily orally on days 1-21 of each 28-day cycle plus low-dose dexamethasone 40 mg per day weekly, and dose modification was performed according to recommendations [13] . Thrombosis prophylaxis with low-dose aspirin was used in all patients. Antibacterial prophylaxis (trimethoprim/sulfamethoxazole) was administered, but prophylactic antifungal and antiviral agents were not used. To identify novel immune cell biomarkers predictive for infections, we prospectively obtained peripheral blood samples at baseline prior to Len-dex treatment. All clinical data were prospectively collected at the time of Len-dex initiation except for cytogenetic and international staging system findings, which were taken from the data established at the time of diagnosis. Written informed consent was obtained from each patient before participation in this study. This study was approved by the Institutional Review Board of the Catholic University of Korea and was conducted in accordance with the Declaration of Helsinki.

Blood samples for cell population analysis were collected immediately before Len-dex initiation [14] . PBMCs were isolated from whole blood samples (10 mL) collected in EDTA-coated tubes by density centrifugation using Ficoll-Paque. PBMCs were processed immediately for analysis. Flow cytometry was used to evaluate the percentages of CD3 + , CD4 + CD161 + , and CD8 + CD161 + T cells, natural killer (NK) cells (CD16 + CD56 + ), and myeloid-derived suppressor cells (MDSCs) [Lin − HLA-DR − CD11b + CD33 + (granulocytic) and HLA-DR − CD14 + (monocytic)]. Anti-CD3-allophycocyanin (APC), anti-CD4-fluorescein isothiocyanate (FITC), anti-CD8phycoerythrin (PE), anti-CD161-PerCP-Cy5.5, anti-CD16-FITC, anti-CD56-PE, and anti-CD14-APC monoclonal antibodies (mAbs) were purchased from eBioscience (San Diego, CA, USA). Anti-lineage cocktail 1 (Lin 1)-FITC, anti-HLA-DR-PerCP, rat anti-mouse CD11b-APC-Cy™7, and mouse anti-human CD33-V450 (BD BioSciences) mAbs were purchased from BD Biosciences (San Jose, CA). CD4 + CD161 + and CD8 + CD161 + T cells were gated on CD3 + cells and are expressed as percentages of lymphocytes. The frequency of HLA-DR − Lin − CD11b + CD33 + and HLA-DR − CD14 + MDSCs is expressed as the percentage of total PBMCs. Flow cytometry was performed using a FACS LSR Fortessa (BD Biosciences).

We investigated infectious complications within every cycle (1 cycle = 28 days) after Len-dex treatment, and the data from that period were analyzed. Infections were classified as microbiologically defined, clinically defined and fever of unknown origin (FUO) as proposed by the Immunocompromised Host Society [15, 16] . Infection types were assessed according to a previous report [9] . Severity of infections was graded using the National Cancer Institute Common Toxicity Criteria grading scheme and grade 1-2 infections were defined as low severity and grade 3-5 infections as high severity. Mortality was defined as infection-related death without refractory or progressive disease. Treatment responses were assessed according to the criteria from the International Myeloma Working Group (IMWG) [17] .

The study objectives were to determine the infection nature, including severity, type, and timing, as well as clinical predictors of infection in RRMM patients receiving Len-dex treatment. In addition, the predictive implications of the composition of immune cell populations prior to Len-dex initiation were explored. The two-tailed Student's t test was used to analyze continuous variables between two groups. Potential risk factors for the occurrence of infections (≥ grade 3) during the first 3 cycles in RRMM patients receiving Len-dex treatment were assessed using logistic regression analysis. Optimal cutoffs for continuous variables were identified using receiver operating characteristic (ROC) curve analysis. To investigate whether the identified markers were independent predictors, covariates with a P value of less than 0.1 in univariate analyses were included in multivariate analysis.

A total of 90 RRMM patients (48 men and 42 women) with a median age of 61 years (range, 29-84 years) who were given Len-dex between January 2014 and February 2015 were analyzed. Patient characteristics are summarized in Table 1 . Median time from diagnosis to Len-dex treatment was 3.2 years (0.5-9.5), and the median number of previous treatment lines was 2.0 (1-7) with 41% having received more than two previous treatment lines. All of the patients were previously exposed to bortezomib, with 54 (60%) patients receiving both bortezomib and thalidomide. Among all patients, 54% had undergone prior autologous stem cell transplantation. With a median administered cycle number of 11 (range, 1-24 cycles), the overall response rate was 80%, and very good partial response or greater occurred in 44% of all 90 patients. Two patients were not evaluable: one was lost to follow-up and the other discontinued Len-dex because of adverse events before evaluation. With a median follow-up of 19.9 months (range, 0.4-24.1 months) for survivors, median progression-free survival and overall survival were 11.7 months and not reached, respectively. The most common cause of discontinuation of treatment was disease progression (44%), followed by adverse events (17%) ( Table 2) .

Of the 90 patients, there were 52 patients with at least 1 episode of infection (≥ grade 2); 30 patients with 1 episode, 13 with 2, 1 with 3, 7 with 4, and 1 with 5; and 38 patients had no episodes of infection. High severity infections (grade 3-5) developed in 30 (33.3%) patients, including 14 patients who experienced severe infections during the first 3 cycles.

Next, a total of 92 episodes of infection during Lendex treatment were evaluated. Of these, 29 (31.5%) were microbiologically defined, 58 (63%) clinically defined, and 5 (5.4%) categorized as FUO. Of 29 microbiologically defined infections, 48.3, 3.4, and 48.3% were bacterial, fungal, and viral in origin, respectively. Variable pathogens were identified in 14 episodes of bacterial origin, including 5 episodes caused by multiple organisms; Escherichia coli (n = 5) was the most ASCT autologous stem cell transplantation, iFLC involved free light chain, Len-dex lenalidomide and low-dose dexamethasone, NA not available, LDH lactate dehydrogenase a High-risk cytogenetics is defined as hypodiploid or deletion of chr13 on conventional cytogenetics or presence of t(4;14), t(14;16), and -17p on fluorescent in situ hybridization and/or conventional cytogenetics. All other cytogenetic abnormalities were considered standard risk b Induction + ASCT was considered one therapeutic line c Patients with measurable serum M protein of at least 1 g per 100 mL were included frequently isolated organism followed by Pseudomonas aeruginosa (n = 4), and Streptococcus pneumonia (n = 4), Klebsiella pneumonia (n = 2). Micrococcus species (n = 1), Staphylococcus aureus (n = 1), Staphylococcus hominis (n = 1), Streptococcus viridans (n = 1), Clostridium difficile (n = 1), Acinetobacter baumannii (n = 1) were isolated. Of 14 microbiologically defined viral infection episodes, 5 episodes were herpes zoster and 9 episodes occurred due to rhinovirus (n = 3), influenza (n = 3), parainfluenza (n = 2), and coronavirus (n = 1). One episode was caused by Pneumocystis jirovecii which was classified as a fungal infection. The respiratory tract (n = 71) was the most common site of infection, followed by skin and soft tissue infection (n = 7). Multiple site infection (n = 7) was also frequently observed, including bacteremia (n = 4). The majority of episodes (57 of 92) were of grade 2 severity, but 35 episodes were of high severity. Admission to the intensive care unit was required in 9.8% of infection episodes, of which two infection episodes resulted in death. Characteristics of episodes of infection are described in Table 3 . During the first 3 cycles, microbiologically defined infections (n = 8), clinically defined infections (n = 14), and FUO (n = 4) occurred. Fourteen (53.8%) of 26 episodes of infection occurring during the first 3 cycles were of high severity (Fig. 1) .

Through longitudinal observation of the epidemiology of infection in RRMM patients receiving Len-dex treatment, we observed that the majority of high severity infections occurred in the first 3 cycles. Accordingly, we compared the frequency and absolute count of various immune cell populations in patients who developed infection (≥ grade 3) during the first 3 cycles of Len-dex treatment with those who did not ( Table 4 ). The frequency of CD3 + CD4 + CD161 + T cells tended to decrease from 4.00 ± 0.28% at baseline to 2.86 ± 0.26% (P = 0.005) and 2.72 ± 0.29% (P = 0.004) after the 2nd and 3rd cycles of therapy, respectively (Fig. 2) . The frequency and absolute count of CD3 + CD4 + CD161 + cells were lower in patients who developed infection (≥ grade 3) during the first 3 cycles (4.26 ± 0.31% vs. 2.82 ± 0.47%, P = 0.047 for the frequency, and 83.78 ± 6.96 vs. 42.41 ± 6.49 cells/μL, P < 0.001 for the absolute count). Patients with infection (≥ grade 3) during the first 3 cycles tended to have a lower absolute count of CD3 + cells (1092.49 ± 67.87 vs. 810.15 ± 128.35 cells/μL, P = 0.078). In contrast, ASCT autologous stem cell transplantation, CR complete response, NA not available, PD progressive disease, PR partial response, SD stable disease, VGPR very good partial response 

To identify risk factors for the occurrence of high severity infections in 90 patients, we evaluated clinical and myeloma-associated variables in univariate analyses (Supplementary Table 1 ). Higher levels of serum creatinine (≥ 2 mg/dL; compared to < 2 mg/dL, P = 0.037) and lower levels of hemoglobin (P < 0.001) and serum albumin (P = 0.061) were associated with the occurrence of high severity infections. These potential risk factors were entered into multivariate logistic regression models with immune parameters, i n cl ud i n g th e f r e q ue nc y a nd a bs ol ute c o un t o f CD3 + CD4 + CD161 + cells and the absolute count of CD3 + cells (Table 5) . High severity infection during the first 3 cycles of Len-dex treatment was significantly predicted by a lower frequency (RR 0.18, P = 0.044) and absolute count (RR 0.13, P = 0.014) of CD3 + CD4 + CD161 + cells.

Although the efficacy and toxicity of lenalidomide for patients with RRMM are well documented, infection remains a leading complication. The results from two pivotal clinical trials found that the incidence rate of infection (≥ grade 3) was approximately 10 to 20% in patients with RRMM receiving Len-Dex [10, 11] . Although the use of low-dose dexamethasone has reduced toxicity while preserving the efficacy of Len-Dex [12] , Kim et al. reported incidence rates (≥ grade 3) of febrile neutropenia, sepsis, and pneumonia of 4.6, 2.7, and 9.1%, respectively, in 110 Korean patients with RRMM in which dexamethasone 160 mg per cycle was most commonly used [18] . Herein, we demonstrated that 52 (57.8%) out of 90 patients experienced at least 1 infection episode during Len-dex treatment, and severe episodes were frequently observed during the first 3 cycles. Our observations of an increased risk of infections in the early treatment period are consistent with findings from previous studies. Many studies, which were conducted before the development of the novel agents, have demonstrated an increased risk of infections in early courses, particularly within 4-6 months following treatment, and a decreased risk of infections after achieving a favorable response to treatment [19] [20] [21] . In patients with MM receiving bortezomib-based treatment, early course therapy was associated with the development of severe bacterial infections [22] . In addition, considering the disease-related and treatmentrelated immune deficits in patients with RRMM, we explored immune cell subsets in association with the occurrence of infection in order to evaluate their emerging potential as cell biomarkers. In this study, lower Hb (< 10 g/dL) was a clinically independent factor associated with the occurrence of infections, and lower frequency (P = 0.044) and absolute count (P = 0.014) of CD3 + CD4 + CD161 + cells in the peripheral blood prior to Len-dex were associated with the occurrence of infection, especially during the first 3 cycles of Lendex therapy.

Recent studies have reported an increased risk of infections with the use of novel agents, suggesting the need for further exploration of these relationships [3, 23] . Kleber et al. showed A unique finding in our study was the suggestion of an immune subtype as a predictive biomarker for the occurrence of infection, especially during the early period of therapy. CD161 is a type II transmembrane glycoprotein with characteristics of the C-type lectin superfamily. This receptor is expressed on NK cells, 25% of all adult peripheral T cells, more than 90% of all peripheral blood monocytes, and on in vitro-derived dendritic cells [24] . We previously evaluated the association of CD161-expressing T cells with the development of acute graft-versus-host disease (AGVHD) after allogeneic SCT and found that a low proportion of CD8 + CD161 + cells and a high ratio of CD4 + CD161 + cells to CD8 + CD161 + cells from peripheral blood at engraftment were associated with the occurrence of AGVHD, with evidence of higher expression of the Th17 transcription factor RORγT in CD4 + CD161 + T cells rather than CD8 + CD161 + T cells [25] . Within the CD4 + subset, CD161 expression is associated with IL-17 production [26] , but other IL-17-producing T cells, such as CD8 + and CD4 − CD8 − double-negative T cells also, express CD161 [27] . Until recently, there has been an agreement that CD161 receptors on NK cells play an inhibitory role [28] [29] [30] , whereas the role on T cells lacks consensus. Recently, we reported that the proportion of pretransplant circulating CD3 + CD4 + CD161 + cells in the allogeneic stem cell transplant setting was associated with the occurrence of neutropenic inf e c t i o n s , w h i c h s u g g e s t e d t h e i m p o r t a n c e o f CD3 + CD4 + CD161 + cells in the rapid immune response to microorganisms before establishment of the post-transplant immune system [31] . The relation between pretransplant CD3 + CD4 + CD161 + cells and the occurrence of early complications was also seen in autologous stem cell transplant setting [32] . In this study, we found that the presence of preexisting CD3 + CD4 + CD161 + cells may play an important role in decreasing the risk of severe infection in patients with RRMM during Len-dex therapy.

Several studies reported lymphopenia as a marker of bacterial infection [22, 33] and viral and fungal infections [34] in MM patients receiving bortezomib therapy, suggesting that lymphopenia indicates a preexisting immunosuppressed condition. However, there is no data on immune subtypes as a predictive factor for infection in RRMM patients treated with Len-dex. Evidence about the prophylactic use of antibiotics in non-neutropenic MM patients is still inconclusive [35] , and prophylactic antibiotics raise the concern of the emergence of antibiotic resistance [36] . Therefore, the prophylactic use of antibiotics may not be needed for all MM patients, but rather only by patients at high risk for the occurrence of infection.

Our results can provide useful information for identifying such high-risk patients who may need the prophylactic use of antiviral and antibiotic agents, especially early during the treatment course for their malignancy.

In conclusion, we found that both patient-and treatmentrelated factors affected the severity, type, and timing of infection in patients with RRMM receiving Len-dex treatment. In particular, a lower frequency and absolute count of CD3 + CD4 + CD161 + cells were associated with the occurrence of infection in the early period of Len-dex therapy. Taking into account risk factors for the occurrence of infection could provide significant information to guide the prophylactic use of antibiotics or increased monitoring for developing infections during Len-dex treatment.

Multiple myeloma

Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party

Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients

Abnormal monoclonal antibodydefined helper/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage

High Th1/Th2 ratio in patients with multiple myeloma

Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire

Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10

Clinical stage-depending decrease of NK cell activity in multiple myeloma patients

Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma

Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy

From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Lenalidomide with dexamethasone treatment for relapsed/ refractory myeloma patients in Korea-experience from 110 patients

Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules

Influence of treatment and response status on infection risk in multiple myeloma

Monocyte dysfunction in patients with multiple myeloma and lymphoplasmacytic disorders is related to serum paraprotein levels

Pretreatment lymphopenia, poor performance status, and early courses of therapy are risk factors for severe bacterial infection in patients with multiple myeloma during treatment with bortezomib-based regimens

Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients

Increased frequency of CD4+ cells expressing CD161 in cancer patients

CD161(+) T cells as predictive markers for acute graftversus-host disease

Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor

is a marker of all human IL-17-producing T-cell subsets and is induced by RORC

Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes

Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor

Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor

Clinical significance of pre-transplant circulating CD3(+) CD4(+) CD161(+) cell frequency on the occurrence of neutropenic infections after allogeneic stem cell transplantation

Circulating CD3+CD4+CD161+ cells are associated with early complications after autologous stem cell transplantation in multiple myeloma

Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens

The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma

Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study

Antibiotic prophylaxis in the era of multidrug-resistant bacteria

Written informed consent was obtained from each patient before participation in this study. This study was approved by the Institutional Review Board of the Catholic University of Korea and was conducted in accordance with the Declaration of Helsinki.

The authors declare that they have no conflict of interest.